启迪药业(000590) - 2025 Q2 - 季度业绩预告

Tus-Holdings Pharmaceutical Group Co., Ltd. 2025 Semi-Annual Performance Forecast I. Expected Performance for the Current Period The company anticipates continued losses in the first half of 2025, with net loss attributable to shareholders expected to narrow from 23.3946 million yuan in the prior year to 15 million - 19 million yuan, indicating a reduced loss margin Performance Forecast for the Current Period | Item | Current Reporting Period (Jan 1 - Jun 30, 2025) | Prior Year Period | | :--- | :--- | :--- | | Net Profit Attributable to Shareholders of Listed Company (yuan) | Loss: 15,000,000 - 19,000,000 | Loss: 23,394,600 | | Net Profit After Deducting Non-Recurring Gains and Losses (yuan) | Loss: 20,000,000 - 25,000,000 | Loss: 24,389,000 | | Basic Earnings Per Share (yuan/share) | Loss: 0.0626 - 0.0793 | Loss: 0.0977 | II. Communication with Accounting Firm The financial data in this performance forecast represents the company's preliminary estimates and has not been audited by an accounting firm - The financial data in this performance forecast is a preliminary estimate and has not been audited by an accounting firm[3] III. Explanation of Performance Changes The company attributes the continued losses in the first half to two core factors: a decline in total operating revenue due to market conditions and increased raw material prices compressing overall gross margin - The company attributes the net profit loss to a decline in total operating revenue caused by market conditions over the past two years[4] - Rising prices of some raw and auxiliary materials are another reason for the decline in overall gross margin and profitability[4] IV. Risk Warning and Other Related Information The company advises investors that this performance forecast is based on preliminary estimates, and the final financial data will be subject to the 2025 semi-annual report, urging caution regarding investment risks - This performance forecast represents preliminary data estimated by the company's finance department and is not the final result[5] - The final accurate financial data will be disclosed in the company's 2025 semi-annual report, reminding investors to be aware of investment risks[6]